IRIS
CASTIGLIONE, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.557
AS - Asia 4.408
EU - Europa 3.807
SA - Sud America 1.318
AF - Africa 105
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
Totale 19.208
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.198
SG - Singapore 1.968
RU - Federazione Russa 1.465
BR - Brasile 1.100
CN - Cina 1.066
IT - Italia 917
VN - Vietnam 526
GB - Regno Unito 340
DE - Germania 276
HK - Hong Kong 267
CA - Canada 254
FI - Finlandia 132
IE - Irlanda 130
IN - India 97
TR - Turchia 96
FR - Francia 94
AR - Argentina 82
BD - Bangladesh 73
MX - Messico 72
SE - Svezia 72
PL - Polonia 71
UA - Ucraina 70
ID - Indonesia 60
NL - Olanda 58
ES - Italia 48
ZA - Sudafrica 47
IL - Israele 43
EC - Ecuador 40
IQ - Iraq 40
AT - Austria 38
JP - Giappone 34
PK - Pakistan 33
AE - Emirati Arabi Uniti 25
PY - Paraguay 23
CO - Colombia 22
LT - Lituania 22
MA - Marocco 19
UZ - Uzbekistan 18
VE - Venezuela 15
RO - Romania 13
CL - Cile 12
PE - Perù 12
BE - Belgio 10
SA - Arabia Saudita 10
DO - Repubblica Dominicana 9
EG - Egitto 9
MC - Monaco 8
UY - Uruguay 8
AU - Australia 7
DK - Danimarca 7
KE - Kenya 7
IR - Iran 6
TN - Tunisia 6
CR - Costa Rica 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
AL - Albania 4
AZ - Azerbaigian 4
CH - Svizzera 4
GY - Guiana 4
JO - Giordania 4
MY - Malesia 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
KR - Corea 3
KZ - Kazakistan 3
NI - Nicaragua 3
NP - Nepal 3
OM - Oman 3
PA - Panama 3
TW - Taiwan 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
GD - Grenada 2
HN - Honduras 2
JM - Giamaica 2
KW - Kuwait 2
LV - Lettonia 2
MD - Moldavia 2
MG - Madagascar 2
NZ - Nuova Zelanda 2
SN - Senegal 2
TH - Thailandia 2
TL - Timor Orientale 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BH - Bahrain 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 19.193
Salva come PNG Salva come JPEG
Città #
Dallas 2.445
Singapore 1.076
Chicago 851
Los Angeles 573
Ashburn 536
Beijing 487
Salt Lake City 393
Hong Kong 256
Buffalo 234
Moscow 209
Tampa 202
Ho Chi Minh City 184
Chandler 181
Elk Grove Village 163
New York 134
Dublin 130
São Paulo 122
Boardman 117
Wilmington 111
The Dalles 108
Hanoi 107
Hefei 107
Munich 102
Beauharnois 89
Milan 88
Fairfield 84
Pisa 82
San Mateo 82
Sterling 81
Rome 73
Lancaster 72
Santa Clara 69
Cambridge 65
Seattle 63
Warsaw 61
Florence 60
Istanbul 58
Houston 57
Montreal 56
London 55
Miami 55
Poplar 52
Helsinki 51
Denver 49
Dulles 48
Brooklyn 47
Stockholm 46
Phoenix 45
Atlanta 43
Ottawa 43
Frankfurt am Main 41
Lappeenranta 41
Portsmouth 40
Orem 39
Stevenage 38
Chennai 36
Turku 35
Rio de Janeiro 34
Tel Aviv 34
Toronto 34
Johannesburg 33
Nuremberg 33
Southend 33
Tokyo 33
Detroit 32
Falls Church 32
Kansas City 31
Mexico City 31
Council Bluffs 30
Lawrence 30
Woodbridge 30
Boston 29
Belo Horizonte 28
Ankara 26
Jacksonville 26
Washington 25
Amsterdam 24
Lucca 24
Manchester 24
Pittsburgh 24
Porto Alegre 24
Da Nang 23
Hangzhou 22
Bologna 21
Guangzhou 21
Palermo 19
Dong Ket 18
Guayaquil 18
San Francisco 18
Curitiba 17
Livorno 17
Tashkent 17
Brasília 16
Genoa 16
Paris 16
Shanghai 16
New Delhi 15
Vienna 15
Ann Arbor 14
Buti 14
Totale 11.809
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.791
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.591
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 657
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 546
A simple echocardiographic score to rule out cardiac amyloidosis 301
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 272
A simple echocardiographic score to rule out cardiac amyloidosis 252
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 250
[Central apneas and cardiovascular diseases] 248
[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells] 224
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 210
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 209
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 204
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 202
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 201
Atrial amyloidosis: mechanisms and clinical manifestations 198
Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis 198
Biomarkers for the diagnosis and management of heart failure 197
Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction 195
Biomarkers for the diagnosis and management of heart failure: New frontiers 187
Cardiovascular disease and COVID-19: les liaisons dangereuses 186
Eligibility for vericiguat in a real‐world, contemporary heart failure population 185
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 184
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 181
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? 179
Role of Imaging in Cardiomyopathies 175
Cardiac magnetic resonance in patients with muscular dystrophies 175
Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern 175
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 174
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 173
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 168
Valvular heart disease in patients with cardiac amyloidosis 166
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 166
Molecular autopsy of sudden cardiac death in the genomics era 166
Disease features and management of cardiomyopathies in women 163
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets 162
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 161
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 159
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 159
RNA-targeting and gene editing therapies for transthyretin amyloidosis 158
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 157
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis 154
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week 154
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 153
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 151
Tissue Characterization in Cardiac Amyloidosis 150
Valve disease in cardiac amyloidosis: an echocardiographic score 150
Cardiac amyloidosis: Innovations in diagnosis and treatment 147
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 147
Sex differences in transthyretin cardiac amyloidosis 146
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 145
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy 145
Current and emerging drug targets in heart failure treatment 144
Cardiovascular toxicity from therapies for light chain amyloidosis 143
Pathophysiology of Cardiac Amyloidosis 140
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 139
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 137
Cardiac Amyloidosis: How Its Epidemiology is Changing 136
Coronary Artery Anomalies 136
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction 134
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 132
Use of biomarkers to diagnose and manage cardiac amyloidosis 131
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 129
Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction 129
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 129
Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis 129
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy 129
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 128
Obstructive sleep apnea and cardiovascular diseases 126
Treatment of cardiac transthyretin amyloidosis: an update 124
What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas 124
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 123
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 123
Chest pain after elective percutaneous coronary intervention as trigger of takotsubo syndrome-a case report 122
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond 122
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis 115
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure? 115
PET and Cardiac Amyloidosis 113
Positron emission tomography in cardiac amyloidosis: current evidence and future directions 112
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 112
Stroke in ATTR cardiac amyloidosis: Does only rhythm matter? 110
Safety and Efficacy of Amiodarone in a Patient With COVID-19 110
Critical Reading of cardiovascular trials with neutral or negative results 109
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 109
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 108
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines 107
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy: Which Cut-Offs? 105
Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is 104
Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician 103
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 101
The unbearable underreporting of comorbidities in heart failure clinical trials 101
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis 99
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 97
The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis? 96
Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study 92
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 92
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 91
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 91
sST2 for Outcome Prediction in Acute Heart Failure: Which Is the Best Cutoff? 91
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 87
Totale 18.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021233 0 0 0 0 0 26 22 24 39 24 49 49
2021/2022544 45 67 17 39 25 62 45 94 58 50 7 35
2022/2023563 33 61 23 50 58 71 23 49 103 22 51 19
2023/2024756 43 15 140 74 47 65 53 31 27 47 31 183
2024/20258.178 51 97 231 132 304 256 611 1.146 434 1.070 2.215 1.631
2025/20268.831 851 2.039 2.152 2.068 1.505 216 0 0 0 0 0 0
Totale 19.328